NASDAQ:SBBP - Strongbridge Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.51 +0.01 (+0.22 %)
(As of 04/18/2019 04:00 PM ET)
Previous Close$4.51
Today's Range$4.45 - $4.66
52-Week Range$3.82 - $8.18
Volume162,400 shs
Average Volume153,572 shs
Market Capitalization$244.30 million
P/E Ratio14.68
Dividend YieldN/A
Beta0.21
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that is used for treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania.

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.03 million
Cash Flow$0.8126 per share
Book Value$2.42 per share

Profitability

Net Income$31.85 million

Miscellaneous

EmployeesN/A
Market Cap$244.30 million
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) posted its quarterly earnings results on Tuesday, February, 26th. The biotechnology company reported $1.64 EPS for the quarter, beating the consensus estimate of ($0.50) by $2.14. The biotechnology company earned $4.51 million during the quarter, compared to analyst estimates of $5.03 million. Strongbridge Biopharma had a net margin of 176.69% and a return on equity of 108.51%. View Strongbridge Biopharma's Earnings History.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Strongbridge Biopharma.

What price target have analysts set for SBBP?

6 brokers have issued 1-year target prices for Strongbridge Biopharma's stock. Their forecasts range from $11.00 to $18.00. On average, they anticipate Strongbridge Biopharma's share price to reach $14.6667 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

What is the consensus analysts' recommendation for Strongbridge Biopharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

News headlines about SBBP stock have been trending positive this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Strongbridge Biopharma earned a media sentiment score of 2.9 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a decline in short interest during the month of March. As of March 15th, there was short interest totalling 417,713 shares, a decline of 40.1% from the February 28th total of 697,310 shares. Based on an average daily volume of 170,555 shares, the short-interest ratio is presently 2.4 days. Currently, 1.2% of the company's stock are short sold. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 52)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 54)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tibra Equities Europe Ltd (0.12%). View Institutional Ownership Trends for Strongbridge Biopharma.

Which major investors are buying Strongbridge Biopharma stock?

SBBP stock was bought by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $4.51.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $244.30 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]om.


MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  211 (Vote Underperform)
Total Votes:  442
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel